Grant

A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined with Radiation and Temozolomide in Patients with Newly-diagnosed Glioblastoma MultiformE:

Abstract

This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.

People

Angelica Erunez
(CD)
Cancer Center Division﹒Research Compliance Administrator II
Charles Hsu
Co-Investigator (COI)
Radiation Oncology﹒Associate Professor, Radiation Oncology - (Clinical Scholar Track)
Baldassarre Stea
Principal Investigator (PI)
Radiation Oncology﹒Department Head
Shona Dougherty
Co-Investigator (COI)
Radiation Oncology﹒Professor

Grant

A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined with Radiation and Temozolomide in Patients with Newly-diagnosed Glioblastoma MultiformE:

Sponsored by Nuvox Pharma, LLC

Related Topics

Abstract

People

Angelica Erunez

Charles Hsu

Baldassarre Stea

Shona Dougherty